“As a company, Zambon has been concentrating its efforts in neuroscience for 10 years now, especially in terms of research and, within neuroscience, in Parkinson’s disease with the aim of improving the quality of life of patients”. Rossella Balsamo, Medical Affairs & Regulatory Zambon Italy and Switzerland, said this at Adnkronos Salute, for the presentation of the new Parkinson Italy Confederation campaign launched on the occasion of the National Day, which is celebrated on 30 November, with the non-conditioning support of the pharmaceutical industry .
“Parkinson’s disease – continues Balsamo – has numbers that are truly alarming as they show the urgency of giving concrete answers to the impact that this pathology has on the patient, on the caregiver and on the society that surrounds the patient”. The prevalence has “doubled in the last twenty years and is the indicator of the global severity of the disease, it has grown by approximately 81% in just twenty years. We realize that it is a very strong and debilitating disease and therefore it is important to find solutions that support the patient’s daily coexistence with the disease. Therefore, in addition to therapies, and therefore to Zambon’s commitment in terms of innovation in scientific research”, the company “also provides support and tools for useful services for patients”.
It is important to “contribute” to reducing “the impact of a disease as complex as Parkinson’s which, even today, is unfortunately accompanied by false beliefs that minimize the real difficulties of the pathology - underlines Balsamo – The campaign of the Parkinson Italy Confederation it goes perfectly in this direction and our commitment to supporting them on this journey starts from here. This is an important first step in a synergistic communication path between Zambon and the Parkinson Italy Confederation which, I hope - he concludes - can continue in the coming years”.
How can patient involvement enhance the development of new therapies for Parkinson’s disease?
Interview Between Time.news Editor and Rossella Balsamo, Zambon Medical Affairs & Regulatory Expert
Editor: Good afternoon, Rossella, and thank you for joining us today. Zambon has dedicated a decade to neuroscience, particularly Parkinson’s disease research. What inspired the company to focus its efforts in this area?
Rossella Balsamo: Good afternoon! Thank you for having me. Our commitment to neuroscience stems from the urgent need to address neurodegenerative diseases, with Parkinson’s disease being a significant focus. We believe in the potential to greatly improve the quality of life for patients, which is why our research efforts are concentrated in this challenging field.
Editor: That’s commendable. Can you highlight some specific projects or innovations Zambon has undertaken in the realm of Parkinson’s research?
Rossella Balsamo: Certainly. Over the past ten years, we’ve engaged in various clinical trials and collaborations to develop therapies that not only tackle the symptoms of Parkinson’s disease but also aim to slow its progression. Our recent studies focus on new medications that optimize patient care, enhance daily functioning, and ultimately increase the quality of life for those affected.
Editor: It’s evident that Zambon prioritizes the well-being of patients. How does the new Parkinson Italy Confederation campaign fit into your efforts?
Rossella Balsamo: The launch of the Parkinson Italy Confederation campaign is a vital step toward raising awareness about Parkinson’s disease. It addresses the social and emotional challenges faced by patients and their families. By collaborating with such initiatives, Zambon aims to promote education, support, and advocacy, further aligning our research goals with the real-life experiences of those living with Parkinson’s.
Editor: This sounds like a significant initiative. What role do you see for patient involvement in Parkinson’s research moving forward?
Rossella Balsamo: Patient involvement is crucial. Their insights can help shape our understanding of the disease, ensuring our research is patient-centered. By actively including patients in discussions and trials, we can better address their needs and preferences, leading to more effective treatments and improved outcomes.
Editor: That’s a refreshing perspective. As Zambon continues its research, what challenges might you face in developing new therapies?
Rossella Balsamo: The path to developing new therapies is fraught with challenges, including regulatory hurdles, funding constraints, and the complexity of neurodegenerative diseases themselves. Parkinson’s is particularly challenging due to its multifaceted nature; thus, we must be innovative and resilient in our approach to finding viable solutions.
Editor: It sounds like a long and rewarding journey. Looking ahead, what are your aspirations for Zambon’s role in the advancement of neuroscience and Parkinson’s treatment?
Rossella Balsamo: My aspiration is for Zambon to lead pioneering research that not only brings forth new therapies but also transforms the overall approach to Parkinson’s care. We aim to be at the forefront of innovations that not only treat the disease but also empower patients and their families, fostering a community of support and hope.
Editor: Thank you, Rossella, for sharing your insights today. Zambon’s commitment to improving the lives of those affected by Parkinson’s disease is truly inspiring. We look forward to seeing how your efforts will evolve in the coming years.
Rossella Balsamo: Thank you for the opportunity to discuss our work. Together, we can make a meaningful difference in the lives of many.